Today: 21 March 2026
Subscribe
Browse Category

Pharmaceuticals 11 December 2025 - 15 December 2025

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals (VRTX) Stock: What to Know Before the Market Opens on Dec. 15, 2025

Vertex Pharmaceuticals shares closed Friday at $452.04, up 1.37%, extending a three-day rally but still 13% below the March high of $519.68. Trading volume topped 1.6 million shares, above the 50-day average. A Morgan Stanley upgrade and optimism over Vertex’s kidney disease pipeline have driven recent swings. New pediatric data for gene-editing therapy Casgevy drew attention at the ASH meeting.
15 December 2025
··
AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie shares closed at $223.32 Friday, down 0.3%, with a market cap near $395 billion. HSBC upgraded the stock to Buy with a $265 target, and Morgan Stanley lifted its target to $269, citing strong growth from Skyrizi and Rinvoq offsetting Humira declines. AbbVie raised 2025 adjusted EPS guidance to $10.61–$10.65 and announced a 5.5% dividend increase to $1.73 per share quarterly.
14 December 2025
··
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer shares closed at $25.85 Friday, Dec. 12, with volume near 50.8 million. The company declared a $0.43 per share dividend for Q1 2026, marking its 349th consecutive payout. New trial data showed Tukysa cut risk of progression or death in HER2+ metastatic breast cancer by about 36%. Investors remain focused on dividend sustainability and pipeline developments.
14 December 2025
··
Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly Stock (LLY) News, Forecasts and Analyst Outlook — Retatrutide Breakthrough, Orforglipron FDA Timeline, and a $6B Manufacturing Bet (Dec. 14, 2025)

Eli Lilly shares last closed at $1,027.51 as investors weigh advances in obesity drugs and new manufacturing plans. Retatrutide, the company’s next-generation obesity treatment, showed 28.7% average weight loss in a Phase 3 trial, with more studies due in 2026. Lilly also announced a $6 billion API plant in Alabama. Orforglipron, an oral obesity drug, may see an accelerated FDA review.
14 December 2025
··
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk shares rebounded this week, rising about 7% in both Copenhagen and U.S. trading after EU regulators backed a higher-dose Wegovy, Ozempic launched in India at a lower price, and the company closed its Akero Therapeutics acquisition. The week began with a sharp selloff on competition fears and a Wall Street downgrade before sentiment reversed midweek.
14 December 2025
····
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK closed at 1,824.5p in London on Dec. 12, up about 1% for the week, despite a 2% drop on Dec. 9. The company secured three positive CHMP opinions in Europe, including for depemokimab in severe asthma and Arexvy’s expanded use in adults 18+. GSK’s U.S. ADR last traded at $48.81. EU decisions on these products are expected in early 2026.
14 December 2025
···
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals said late Friday the FDA approved CARDAMYST (etripamil) as the first self-administered nasal spray for PSVT. MIST shares closed down 18.3% at $2.41 after volatile trading and heavy volume, but rebounded modestly after hours. CARDAMYST is expected in pharmacies in Q1 2026. In a Phase 3 trial, 64% of patients converted to normal rhythm within 30 minutes, compared to 31% on placebo.
14 December 2025
··
Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck shares closed at $100.30 on Friday, up 1.3% for the day and 0.6% for the week, rebounding after early losses tied to vaccine-policy headlines and RSV therapy scrutiny. The stock gained despite broad market declines. Merck received a positive EU CHMP opinion for expanded use of Winrevair, while the FDA launched new safety reviews of its RSV preventive therapies for infants.
13 December 2025
··
Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Pfizer shares closed at $25.85 Friday, up 0.19%, after announcing a global obesity drug deal with YaoPharma and reporting positive Phase 3 data for breast cancer drug Tukysa. The company also highlighted strong hemophilia trial results and declared a $0.43 per share dividend, payable March 6, 2026. Trading volume reached about 23 million shares.
13 December 2025
···
Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson shares closed at $211.58 on Dec. 12, 2025, up 4.9% for the week after an FDA approval for AKEEGA in prostate cancer and new multiple myeloma data. The stock outperformed the broader market despite renewed talc litigation risk. A Federal Reserve rate cut earlier in the week supported large healthcare stocks. JNJ traded as high as $212.27 intraday Friday.
13 December 2025
··
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly shares closed at $1,027.51 Friday, up about 3% for the week after late-stage trial data showed its obesity drug retatrutide delivered nearly 29% average weight loss in patients with knee osteoarthritis. The stock rebounded from an early-week dip, outperforming the broader market as investors weighed drug tolerability and future pricing strategy.
13 December 2025
···
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST nasal spray for on-demand treatment of PSVT in adults, marking the first new U.S. therapy for the condition in over 30 years. The company expects CARDAMYST in pharmacies by Q1 2026. MIST shares were volatile ahead of the decision and ended the week lower despite the approval.
13 December 2025
··
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly shares closed at $1,027.51, up 1.8% Friday, and traded near $1,028–$1,029 after hours following a European regulatory panel’s recommendation to expand Mounjaro use to children 10 and older with type 2 diabetes. Volume was about 3.2 million shares. The stock remains 7.6% below its 52-week high set in late November.
12 December 2025
··
Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck shares rose 0.69% to $99.69 by midday Friday after the European Medicines Agency’s CHMP recommended expanded approval for WINREVAIR in pulmonary arterial hypertension. The stock remains about 6% below its late-November high. Investors weighed the regulatory boost against ongoing legal issues for Keytruda and shifting vaccine policy headlines. Merck expects a final EU decision on WINREVAIR in early 2026.
12 December 2025
···
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals shares closed at $2.95 on Dec. 11, up 10.49% with about 7.54 million shares traded, ahead of an FDA decision on CARDAMYST nasal spray for PSVT due Dec. 13. The stock traded around $2.98 pre-market Dec. 12, rebounding from a 52-week low of $0.625 after an FDA rejection earlier in 2025 and subsequent resubmission.
12 December 2025
·
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly shares traded near $1,009 Friday after its obesity drug retatrutide showed 28.7% average weight loss in a Phase 3 trial, though with notable discontinuation rates. Reuters reported FDA leaders pushed to speed review of Lilly’s oral GLP-1 drug orforglipron, raising internal concerns. The company is building a $6 billion Alabama plant to boost manufacturing. Analyst price targets remain supportive but vary widely.
12 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly shares closed Thursday near $1,006 after new Phase 3 data showed its obesity drug retatrutide cut body weight by up to 28.7% in patients with knee osteoarthritis. The company announced a $6 billion plant in Alabama and reported Q3 revenue up 54% to $17.6 billion. Mounjaro will be covered by China’s national health insurance from January.
11 December 2025
···
Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals announced Mario Alberto Accardi will become CEO on January 1, 2026, as the company’s orexin drug program nears pivotal studies. Shares fell 8.4% to about $27 after the news. Current CEO Saurabh Saha will move to an advisory role. The company’s lead candidate, ORX750, is set for registrational trials in early 2026.
11 December 2025
··
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals shares fell 6% to US$9.33 in New York on December 11, near a 52-week low, despite trailing 12-month revenue of US$664 million and a new clinical partnership with Varian. The company faces SEC scrutiny, an FDA setback, and multiple class-action lawsuits, but continues to report late-stage oncology progress and expanding collaborations.
11 December 2025
···
1 … 25 26 27 28 29 … 38

Stock Market Today

  • HKEX Considers Confidential IPO Applications to Boost Listings
    March 20, 2026, 10:14 PM EDT. The Hong Kong Stock Exchange (HKEX) is seeking feedback on proposals to allow all companies to file initial public offering (IPO) applications confidentially. Currently, only select firms benefit from this confidentiality. Investment banks and brokers back the change, expecting it to attract more listings and strengthen Hong Kong's status as a global financial hub. Since 2013, HKEX requires public disclosure of listing documents upon application submission, detailing corporate history, business models, and finances. Market participants argue that aligning with practices on other global exchanges could enhance privacy for issuers during sensitive early stages, potentially drawing smaller and innovative firms.
Go toTop